Resonance Speci.

how big is Resonance Speci.?

As of Jun 06, Resonance Specialities Ltd has a market capitalization of 136.45 Cr, with recent net sales of 77.80 Cr and net profit of 6.58 Cr over the last four quarters. Shareholder's funds are 57.50 Cr, and total assets amount to 73.77 Cr.

Market Cap: As of Jun 06, Resonance Specialities Ltd has a market capitalization of 136.45 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 77.80 Cr, while the sum of Net Profit for the same period is 6.58 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 57.50 Cr, and Total Assets amount to 73.77 Cr.

What does Resonance Speci. do?

Resonance Specialities Ltd is a micro-cap company in the specialty chemicals sector, primarily manufacturing Pyridine and its derivatives. As of March 2025, it reported net sales of 24 Cr and a net profit of 3 Cr, with a market cap of Rs 141 Cr.

Overview: <BR>Resonance Specialities Ltd is a micro-cap company operating in the specialty chemicals industry, focusing on the manufacturing and marketing of Pyridine and its derivatives, Picoline, Cynopyridine, and some bulk drugs.<BR><BR>History: <BR>The company was incorporated in June 1989 as a Private Limited Company in Maharashtra and converted into a Public Limited Company in March 1990. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 24 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 141 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.04 <BR>Return on Equity: 11.10% <BR>Price to Book: 2.19 <BR><BR>Contact Details: <BR>Address: Plot No 54D Kandivli, Industrial Estate Kandivali W Mumbai Maharashtra : 400067 <BR>Email: info@resonancesl.com <BR>Website: http://www.resonancesl.com

When is the next results date for Resonance Speci.?

No Upcoming Board Meetings

Has Resonance Speci. declared dividend?

Yes, Resonance Specialities Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of August 1, 2023. Despite this, the dividend yield is 0%, but the company has shown strong price performance with a total return of 184.54% over the last 5 years.

Resonance Specialities Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 01 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 16.05%, with no dividend return, resulting in a total return of 16.05%.<BR><BR>Over the past year, the price return was 16.28%, with no dividend return, leading to a total return of 16.28%.<BR><BR>In the 2-year period, the price return was 48.88%, with a dividend return of 1.17%, culminating in a total return of 50.05%.<BR><BR>For the 3-year period, the price return was -20.53%, with a dividend return of 1.39%, resulting in a total return of -19.14%.<BR><BR>In the 4-year timeframe, the price return was -24.97%, with a dividend return of 2.05%, leading to a total return of -22.92%.<BR><BR>Finally, over the last 5 years, the price return was 177.78%, with a dividend return of 6.76%, resulting in a total return of 184.54%.<BR><BR>Overall, while Resonance Specialities Ltd has declared a dividend, the dividend yield remains at 0%. The total returns show a positive trend over the last 5 years, indicating strong price performance despite fluctuations in dividend returns across different periods.

Who are the peers of the Resonance Speci.?

Peers of Resonance Speci. include Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Deepak, Deep Polymers, KKalpana Inds., and Alkali Metals. SRF has the highest 1-year return at 30.72%, while Deep Polymers has the lowest at -36.06%; Resonance Speci. has a return of 15.01%.

Peers: The peers of Resonance Speci. are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Deepak, Deep Polymers, KKalpana Inds., and Alkali Metals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite and Deepak, while Good management risk is found at Pidilite Inds. and SRF. Average management risk is present at Gujarat Fluoroch, Himadri Special, and Alkali Metals, while Below Average management risk is seen at Deep Polymers and KKalpana Inds. In terms of Growth, Excellent growth is noted at Deep Polymers, Good growth at Himadri Special, and Average growth at Pidilite Inds. and SRF, while Below Average growth is observed at Gujarat Fluoroch, Deepak Nitrite, Deepak, KKalpana Inds., and Alkali Metals. For Capital Structure, Excellent is seen at Pidilite Inds., SRF, Deepak Nitrite, Deepak, and Resonance Speci., while Good is noted at Gujarat Fluoroch and Himadri Special, and Below Average at Deep Polymers, KKalpana Inds., and Alkali Metals.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SRF at 30.72%, while the lowest is Deep Polymers at -36.06%. Resonance Speci. has a 1-year return of 15.01%, which is higher than Deep Polymers but lower than SRF. Additionally, peers with negative six-month returns include Deep Polymers, Deepak Nitrite, and KKalpana Inds.

What is the technical trend for Resonance Speci.?

As of June 6, 2025, Resonance Speci. shows a mildly bullish trend supported by positive weekly and monthly MACD and Bollinger Bands, despite some short-term weakness indicated by daily moving averages.

As of 6 June 2025, the technical trend for Resonance Speci. has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bullish. Both the weekly and monthly Bollinger Bands are bullish, indicating upward momentum. The Dow Theory also reflects a mildly bullish stance on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which suggests some short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the positive signals from MACD and Bollinger Bands, despite some mixed signals from moving averages.

Who are in the management team of Resonance Speci.?

As of March 2023, the management team of Resonance Speci. includes Archana Yadav (Chairman), Prashant Godha, Raj Kamal Prasad Verma, Ajay Patadia (Independent Directors), Charchit Jain (Whole Time Director & CFO), Nilesh Jain (Non-Executive Director), and Vaibhavi Rajeshirke (Company Secretary & Compliance Officer). Each member plays a key role in the company's governance and operations.

As of March 2023, the management team of Resonance Speci. includes the following individuals:<BR><BR>1. Archana Yadav - Chairman & Independent Director<BR>2. Prashant Godha - Non-Executive & Non-Independent Director<BR>3. Raj Kamal Prasad Verma - Independent Director<BR>4. Ajay Patadia - Independent Director<BR>5. Charchit Jain - Whole Time Director & CFO<BR>6. Nilesh Jain - Non-Executive Director<BR>7. Vaibhavi Rajeshirke - Company Secretary & Compliance Officer<BR><BR>Each member has distinct roles within the company, contributing to its governance and operational management.

Who are the top shareholders of the Resonance Speci.?

The top shareholders of Resonance Speci. are Makers Laboratories Limited with 45.48%, followed by Avignon Exim Private Limited at 2.22%. Individual investors own 33.22%, and there is one foreign institutional investor with a 0.03% stake, while mutual funds do not hold any shares.

The top shareholders of Resonance Speci. include Makers Laboratories Limited, which holds the largest stake at 45.48%. The highest public shareholder is Avignon Exim Private Limited, with a holding of 2.22%. Additionally, individual investors collectively own 33.22% of the company. There are no pledged promoter holdings, and the company has one foreign institutional investor (FII) holding a small stake of 0.03%. Mutual funds do not hold any shares in the company.

Are Resonance Speci. latest results good or bad?

Resonance Specialities' latest results show strong year-on-year growth with a 176.27% increase in net profit and a 22.95% rise in revenue. However, there are concerns due to a 46.73% decline in net profit and a 12.11% drop in revenue quarter-on-quarter, alongside reduced operating margins, indicating potential challenges ahead.

The latest results for Resonance Specialities present a mixed picture. On one hand, the company reported a net profit of ₹1.63 crore for Q2 FY26, which is a remarkable increase of 176.27% year-on-year, indicating strong operational performance compared to the same quarter last year. Additionally, revenue grew by 22.95% year-on-year to ₹21.27 crore, reflecting the company's ability to capitalize on improving demand in the specialty chemicals sector.<BR><BR>However, there are significant concerns regarding the quarter-on-quarter performance. The net profit declined by 46.73% from the previous quarter, and revenue fell by 12.11%. This sequential weakness raises questions about the sustainability of the recent growth and suggests potential challenges in maintaining profitability. Furthermore, the operating margin saw a sharp contraction, decreasing from 17.52% in Q1 FY26 to 11.99% in Q2 FY26, which is a notable drop and reflects increased operating costs.<BR><BR>In summary, while the year-on-year growth figures are impressive, the quarter-on-quarter declines in both profit and revenue, along with margin compression, indicate underlying issues that investors should monitor closely. The overall sentiment could be viewed as cautious, given the volatility in performance metrics.

How has been the historical performance of Resonance Speci.?

Resonance Speci. has shown fluctuating financial performance, with net sales increasing to 77.81 Cr in Mar'25 from 55.30 Cr in Mar'24, while profit after tax rose to 6.57 Cr. However, the company faced cash flow challenges, reporting a net cash outflow of 1.00 Cr in Mar'25 despite overall growth.

Answer:<BR>The historical performance of Resonance Speci. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Resonance Speci. has experienced varying net sales, with a notable increase to 77.81 Cr in Mar'25 from 55.30 Cr in Mar'24, although it had previously dipped to 58.81 Cr in Mar'23. The total operating income followed a similar pattern, reaching 77.81 Cr in Mar'25. The company's total expenditure, excluding depreciation, rose to 67.21 Cr in Mar'25 from 50.49 Cr in Mar'24, impacting the operating profit, which increased to 10.60 Cr in Mar'25 from 4.81 Cr in Mar'24. Profit before tax also saw an increase to 8.88 Cr in Mar'25, up from 3.96 Cr in Mar'24, while profit after tax rose to 6.57 Cr from 2.97 Cr in the same period. The earnings per share (EPS) improved significantly to 5.69 in Mar'25 from 2.57 in Mar'24. On the balance sheet, total assets increased to 75.55 Cr in Mar'25, up from 73.77 Cr in Mar'24, with total liabilities also rising to 75.55 Cr. The company reported a net cash outflow of 1.00 Cr in Mar'25, indicating challenges in cash flow management despite the growth in sales and profits.

Is Resonance Speci. overvalued or undervalued?

As of December 4, 2025, Resonance Specialty Chemicals is considered overvalued with a PE ratio of 15.31 and an EV to EBITDA of 10.26, despite recent stock performance outpacing the Sensex, indicating its current market price does not reflect an attractive investment opportunity compared to peers like Solar Industries and Godrej Industries.

As of 4 December 2025, the valuation grade for Resonance Specialty Chemicals has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.31, an EV to EBITDA of 10.26, and a PEG ratio of 0.24, which suggests that while the company may have growth potential, its current price does not reflect an attractive investment opportunity.<BR><BR>In comparison to its peers, Resonance Specialty Chemicals stands out as overvalued, especially when compared to Solar Industries, which has a PE ratio of 88.66, and Godrej Industries, which is rated attractive with a PE of 35.01. The recent stock performance shows that Resonance has outperformed the Sensex over the past week and month, but its longer-term returns have lagged behind, reinforcing the notion that the current valuation may not be justified given the overall market context.

Should I buy, sell or hold Resonance Specialities Ltd?

Why is Resonance Specialities Ltd falling/rising?

As of 02-Feb, Resonance Specialities Ltd's stock price is at 106.90, reflecting a 0.19% increase. The stock has outperformed the Sensex over the past week and month, showing strong upward trends despite a decrease in investor participation.

As of 02-Feb, Resonance Specialities Ltd's stock price is rising, currently at 106.90, reflecting a change of 0.2 (0.19%) upward. This positive movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, with a return of +14.27% compared to the Sensex's +0.16%. Additionally, the stock has shown a solid performance over the past month, gaining +3.79% while the Sensex has declined by -4.78%. Year-to-date, Resonance Specialities Ltd has also increased by +5.32%, contrasting with the Sensex's -4.17% decline.<BR><BR>Moreover, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend. However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by -9.77% against the 5-day average. Despite this decline in participation, the overall performance metrics suggest that the stock is experiencing a positive trajectory in the market.

Which are the latest news on Resonance Speci.?